Australia And New Zealand Surgical And Respiratory Mask Market Size to Exceed USD 357.3 Mn by 2032

The Australia And New Zealand Surgical And Respiratory Mask Market, estimated at USD 224.0 Mn in 2025, is expected to exhibit a CAGR of 6.9% and reach USD 357.3 Mn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

The increase in the prevalence of lung diseases such as asthma and various infection such as bacterial or viral infections like Covid-19 is expected to provide lucrative growth opportunities for players. Thus, key market players are focused on adopting growth strategies such as collaboration, and acquisitions, which will drive the Australia & New Zealand Surgical and Respiratory Mask Market. For instance, according to the WHO (World Health Organization), there have been 11,381,171 confirmed cases of COVID-19 with 20,866 deaths in Australia. Whereas, in New Zealand, there have been 2,306,943 confirmed cases of COVID-19 with 2,942 deaths.

Australia & New Zealand Surgical and Respiratory Mask Market–Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets.

COVID-19 had a positive impact on the Australia & New Zealand surgical and respiratory mask market due to an increase in infectious diseases such as chlamydia. For instance, in July 2025, according to the American Institute of Health and Welfare, almost 702,000 cases of notifiable diseases were reported to the National Notifiable Diseases Surveillance System (NNDSS) in 2025. Four diseases accounted for 89% of notifications to Australian health authorities in 2025: COVID-19–almost 471,000 notifications chlamydia (a sexually transmissible infection)–almost 86,000 notifications campylobacter (a gastrointestinal infection)–more than 37,000 notifications and varicella zoster (which causes chickenpox and shingles)–more than 33,000 notifications combined.

Australia & New Zealand Surgical and Respiratory Mask Market: Key Developments

In April 2025, a face mask testing facility was established in Adelaide–the first in Australia–to support the production of millions of respirator and surgical masks by the Detmold Group to help stop the spread of COVID-19. The State and Commonwealth Governments commissioned Detmold, a packaging company, to establish a respirator (P2/N95 masks) and a surgical mask (Level 3) manufacturing capability in Brampton producing 45 million face masks for (South Australia) SA Health and 100 million for the Federal Government’s National Medical Stockpile.

In July 2025, Detmold Medical, a manufacturer, source, and supply specialist of personal protective equipment, disposable products, and consumables to the medical industry delivered the first order of L3 (Level 3) face masks to SA Health, a provider of health reform, public health services, health and medical research, policy development and planning. With an increased need for personal protective equipment during the coronavirus health crisis, the Detmold Group set up for local production of face masks in record time.

In February 2025, AirPop, the premium high-performance face mask brand STRAX holds a five-year global exclusive distribution agreement for, has recently secured key retail channels in the United States, Canada, and Australia.

Browse 27 Market Data Tables and 21 Figures spread through 115 Pages and in-depth TOC on “Australia & New Zealand Surgical and Respiratory Mask Market”, By Product Type (Respiratory Mask (Disposable Respiratory Mask, and Reusable Respiratory Mask), Surgical Mask (Disposable Surgical Mask, and Reusable Surgical Mask), By Sales Channel (Offline and Online).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/australia-and-new-zealand-surgical-and-respiratory-mask-market-3720

Key Takeaways of the Australia & New Zealand Surgical and Respiratory Mask Market:

The Australia & New Zealand surgical and respiratory mask market is expected to exhibit a CAGR of 6.9% during the forecast period. Infectious diseases are expected to grow in the Australia & New Zealand surgical and respiratory mask market over the forecast period. For instance, according to the World Health Organization, the coronavirus disease (COVID-19) affected 5,354 people in Australia & New Zealand as of March 2025.

Major players operating in the Australia & New Zealand surgical and respiratory mask market include 3M Company, Smith & Nephew Plc., O&M Halyard or its affiliates, Mölnlycke Health Care AB, Medline Industries, Inc., Ansell LTD, and WPT Nonwovens Corp.